AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35722047
Drug: 12-week structured
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week structured physical activity programme during chemotherapy
Trial: 35722126
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity integrated into learning (daily PA unit of 45 min over 3 years)
Trial: 35722822
Drug: DS-1001 (125-1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1001 (125-1400 mg orally, twice daily)
Trial: 35725143
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss before treatment
Trial: 35725143
Drug: Weight stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight stable before treatment
Trial: 35725143
Drug: Weight gain
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight gain before treatment
Trial: 35725262
Drug: Paracetamol usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol usage
Trial: 35725542
Drug: Standardized prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized prolonged discharge prescription forms plus education
Trial: 35725623
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa
Trial: 35725670
Drug: Serum steroid
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum steroid profiling including 21-deoxycortisol and cosyntropin stimulation test with 17OHP
Trial: 35725917
Drug: Enteral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral iron supplementation (median cumulative intake 58.5 mg/kg at 28 days, 235.8 mg/kg through 36 weeks)
Trial: 35725917
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron supplementation (median cumulative intake 3.1 mg/kg at 28 days, 3.56 mg/kg through 36 weeks)
Trial: 35726793
Drug: Combination ipilimumab/nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ipilimumab/nivolumab followed by maintenance nivolumab
Trial: 35726793
Drug: Combination ipilimumab/nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ipilimumab/nivolumab
Trial: 35726971
Drug: Concentrated parenteral
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated parenteral nutrition (PN)
Trial: 35726971
Drug: Original parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original parenteral nutrition (PN)
Trial: 35727618
Drug: mHealth patch
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth patch device with AI arrhythmia analysis for AF detection
Trial: 35727622
Drug: Digitally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitally delivered treatment program for LBP (3 months duration)
Trial: 35727633
Drug: Tumor-infiltrating lymphocytes
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating lymphocytes (TILs) infusion after concurrent chemoradiotherapy (CCRT) plus i.m. IL-2 injections
Trial: 35728746
Drug: Biologics (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics (including omalizumab, benralizumab, mepolizumab, dupilumab, reslizumab)
Trial: 35728746
Drug: Biologics (switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics (switching biologics)
Trial: 35728746
Drug: Non-anti-immunoglobulin E
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anti-immunoglobulin E biologics
Trial: 35729005
Drug: Dostarlimab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (500 mg IV every 3 weeks for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity
Trial: 35729429
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment strategies, invasive procedures, revascularisation therapies, and use of mechanical circulatory support devices, including extracorporeal cardiopulmonary resuscitation.
Trial: 35729673
Drug: D-allulose (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-allulose (8.5 g consumed before iftar meal)
Trial: 35731948
Drug: Pyrazinamide AUC0-24
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide AUC0-24 of 379 mg × h/L
Trial: 35734087
Drug: Primary 2-dose
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary 2-dose series of COVID-19 mRNA vaccination during pregnancy
Trial: 35735167
Drug: Friend-oriented networks
RxNorm normalized name: Fisherman's Friend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friend-oriented networks with weekly contact
Trial: 35737639
Drug: CC-90011 (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90011 (once per week in 28-day cycles)
Trial: 35737873
Drug: Ixazomib in
RxNorm normalized name: Product containing ixazomib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib in combination with cyclophosphamide and dexamethasone
Trial: 35737873
Drug: Ixazomib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib maintenance after 12 cycles of treatment
Trial: 35737873
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to alternate therapy
Trial: 35738999
Drug: Trametinib 2mg
RxNorm normalized name: TRAMETINIB 2MG ORAL TAB
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 2mg oral daily along with TAS-102 starting at 35 mg/m
Trial: 35740079
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (LDRT) 0.5 Gy
Trial: 35740603
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) at 3 mg/m²
Trial: 35740603
Drug: Fractionated doses
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated doses of Gemtuzumab ozogamicin (GO3)
Trial: 35740603
Drug: CLAG-M (cladribine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLAG-M (cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone)
Trial: 35742400
Drug: e-OTCAT program
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-OTCAT program during 12 consecutive weeks since the beginning of chemotherapy
Trial: 35743360
Drug: Preoperative platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative platelet reactivity to P2Y12 inhibitors
Trial: 35747193
Drug: PT-112 (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT-112 (125 mg/m)
Trial: 35747402
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma mannose-binding lectin (p-MBL) levels (≤500 µg/l) in RPL patients
Trial: 35747402
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma mannose-binding lectin (p-MBL) levels (>3000 µg/l) in RPL patients
Trial: 35747402
Drug: Intermediate plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate plasma mannose-binding lectin (p-MBL) levels (501-3000 µg/l) in RPL patients
Trial: 35747712
Drug: Sintilimab in
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab in combination with concurrent chemoradiotherapy (cCRT)
Trial: 35747751
Drug: Oral Co-Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3
Trial: 35748318
Drug: Postprandial studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postprandial studies with whole-body positron emission tomography/computed tomography (PET/CT) using oral [18F]fluoro-thia-heptadecanoic acid and dynamic PET/CT with intravenous [11C]palmitate
Trial: 35748699
Drug: Fazirsiran 200
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran 200 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohorts 1 and 2)
Trial: 35748699
Drug: Fazirsiran 100
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran 100 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohort 1b)
Trial: 35748707
Drug: IV ganaxolone
RxNorm normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ganaxolone (low, 500 mg/day; medium, 650 mg/day; high, 713 mg/day)
Trial: 35750354
Drug: SPL-108 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL-108 with weekly paclitaxel
Trial: 35750559
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior intravesical therapy
Trial: 35750695
Drug: CX-5461 (G-quadruplex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-5461 (G-quadruplex stabilizer)
Trial: 35750958
Drug: Intravenous Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Vitamin C (IVC) 1-100 g in healthy volunteers
Trial: 35750958
Drug: Intravenous Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Vitamin C (IVC) 25-100 g in oncology participants
Trial: 35750958
Drug: Intravenous Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Vitamin C (IVC) 100 g
Trial: 35750958
Drug: Intravenous Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Vitamin C (IVC) up to 100 g
Trial: 35751496
Drug: nab-paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel at 260 mg/m² combined with S-1 (80-120 mg/day, d1-14, q3w) for 6 cycles followed by 8 cycles of S-1 monotherapy
Trial: 35751496
Drug: nab-paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel at 180 mg/m²
Trial: 35753092
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy and statins adherence
Trial: 35756891
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for clinical monitoring of patients prescribed home oxygen therapy
Trial: 35758418
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily PrEP users)
Trial: 35759134
Drug: ASP1650 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP1650 (1000 mg/m)
Trial: 35760939
Drug: SARS-CoV-2 vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccination (various vaccines including Gam-COVID-Vac, ChAdOx1 nCoV-19, BBIBP-CorV)
Trial: 35762834
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5)
Trial: 35762890
Drug: Transarterial radioembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial radioembolization (TARE) with yttrium 90, details on dosage and duration not available.
Trial: 35763351
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol patches (200 µg/day) for 3 weeks postpartum
Trial: 35763351
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches for 3 weeks postpartum
Trial: 35763667
Drug: Involved-field radiotherapy
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for SERs after 3 chemotherapy cycles.
Trial: 35763667
Drug: No involved-field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No involved-field radiotherapy (IFRT) for SERs after 3 chemotherapy cycles.
Trial: 35763667
Drug: Involved-field radiotherapy
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for RERs after 3 chemotherapy cycles.
Trial: 35763667
Drug: No involved-field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No involved-field radiotherapy (IFRT) for RERs after 3 chemotherapy cycles.
Trial: 35764393
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of mRNA vaccine administered within 6 months after the second dose
Trial: 35764393
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of mRNA vaccine
Trial: 35764393
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of mRNA vaccine
Trial: 35764638
Drug: Lentiviral-transduced autologous
RxNorm normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral-transduced autologous hematopoietic stem cells following busulfan (6 mg/kg total) conditioning
Trial: 35764637
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of BNT162b2 (BB)
Trial: 35764637
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of CoronaVac (CC)
Trial: 35764637
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of BNT162b2 (B)
Trial: 35764637
Drug: CoronaVac (CC)
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (CC)
Trial: 35764637
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (BNT162b2 and CoronaVac)
Trial: 35764796
Drug: Decentralized clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decentralized clinical trial (DCT) with oral anticoagulation adherence (OACA)
Trial: 35764995
Drug: Survey during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey during maintenance therapy (T2)
Trial: 35764995
Drug: Survey near
RxNorm normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey near treatment completion (T3)
Trial: 35765145
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of donor-derived cell-free DNA (dd-cfDNA) fraction and quantity
Trial: 35767123
Drug: No inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhaled corticosteroids (ICS) treatment
Trial: 35767182
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg per day)
Trial: 35767182
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with radioactive iodine (RAI) therapy
Trial: 35767205
Drug: Sitravatinib (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib (10-200 mg)
Trial: 35767205
Drug: Sitravatinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib (150 mg)
Trial: 35767439
Drug: Oncolytic virus
RxNorm normalized name: Reovirus type 3 dearing oncolytic virus without transgenes
DrugBank: Pelareorep (DB17284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncolytic virus DNX-2401 infusion followed by radiotherapy
Trial: 35768023
Drug: CT-STAR (cone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiation therapy)
Trial: 35768023
Drug: nonadapted CT-guided
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonadapted CT-guided stereotactic body radiation therapy (SBRT)
Trial: 35768164
Drug: TCR-transduced T-cell
RxNorm normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-transduced T-cell product (TBI-1301) with a dose of 5×10
Trial: 35768859
Drug: Ziv-aflibercept 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept 1.25 mg (0.05 ml) administered by intravitreal injection monthly for 6 months
Trial: 35769244
Drug: Generic once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic once-daily tacrolimus
Trial: 35769360
Drug: DISE-guided CPAP
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISE-guided CPAP titration
Trial: 35769360
Drug: CSC CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSC CPAP titration
Trial: 35769368
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no alteplase treatment)
Trial: 35771301
Drug: Aflibercept combined
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept combined with docetaxel (75 mg/m²)
Trial: 35771301
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m²)
Trial: 35771572
Drug: Decreased default
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased default number of opioid doses from 30 to 12 in pediatric otolaryngology patients post-intervention.
Trial: 35771573
Drug: Venlafaxine extended
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended release (37.5 mg to 300 mg daily for up to 12 weeks)
Trial: 35771832
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TMT and video game multitask training (VGMT)
Trial: 35772170
Drug: Rondoraptivon pegol
RxNorm normalized name: Rondoraptivon pegol
DrugBank: BT200 (DB18333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rondoraptivon pegol (3 mg subcutaneously on days 1, 4, and 7, followed by 6 to 9 mg weekly until day 28)
Trial: 35772177
Drug: O3AEE (omega-3-acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O3AEE (omega-3-acid ethyl esters) 2 g/day
Trial: 35772417
Drug: Daily PrEP
RxNorm normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PrEP (tenofovir disoproxil 245 mg and emtricitabine 200 mg, one pill per day)
Trial: 35772417
Drug: On-demand PrEP
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand PrEP (following IPERGAY dosing recommendation)
Trial: 35772429
Drug: SHR2554 (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 (350 mg twice daily)
Trial: 35772429
Drug: SHR2554 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 (various doses)
Trial: 35772429
Drug: SHR2554 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 (all doses)
Trial: 35772805
Drug: Gadolinium administration
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium administration (20 and 120 minutes)
Trial: 35772852
Drug: Intraventricular enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular enzyme replacement therapy (ERT) with cerliponase alfa
Trial: 35772853
Drug: sacubitril/valsartan 24/26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 24/26 mg twice a day
Trial: 35774932
Drug: Community-based, respondent-driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based, respondent-driven sampling (RDS) survey with HCV screening and immediate treatment
Trial: 35775211
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer therapy with physical activity (PA) participation
Trial: 35775211
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer therapy without physical activity (inactive)
Trial: 35775211
Drug: Pre-treatment physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment physical activity scores